Ostendo Technologies, Inc. and Veea Inc. to Merge

Ostendo Technologies, Inc., and Veea Inc. today announced the signing of a letter of intent to combine Ostendo’s

Intuitive Venture PartnersMarch 6, 2023Ostendo, 2023

Guerrilla RF Completes Final Closing of $9.2 Million Private Placement Equity Financing

Guerrilla RF, Inc. (OTCQX: GUER), a leading provider of state-of-the-art RF and microwave communications

Intuitive Venture PartnersMarch 6, 2023Guerilla, 2023

Aeluma Achieves Photodetector Performance Milestone with its Large-Diameter Wafer Manufacturing Platform

Aeluma, Inc. (the "Company") (OTCQB:ALMU), a semiconductor company specializing in scalable, cost-effective

Intuitive Venture PartnersMarch 6, 2023aeluma, 2023

Entera Bio Announces Execution of Key Regulatory Milestones for EB613, the First Oral Anabolic Drug Proposed for the Treatment of Osteoporosis; Miranda Toledano Assumes CEO Position

Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered peptides and therapeutic proteins, announced today the execution of the following key milestones:

Intuitive Venture PartnersJuly 18, 20222022, entera bio

Aeluma, Inc. Names Former Head of Business Development for Continental's LiDAR Product Line, Thomas Laux, as Vice President of Business Development

Aeluma, Inc., announced today that it has named Thomas Laux as Vice President of Business Development.

Intuitive Venture PartnersMay 3, 2022aeluma, 2022

Virsec Secures $100 Million Show of Force Investment as it Redefines How Software is Secured

Virsec Systems, Inc. secures $100 million “show of force” investment as it redefines how software is secured.

Intuitive Venture PartnersJuly 14, 20212021, virsec

Aeluma, Inc. Raises $8 Million and Completes Reverse Merger

Aeluma, Inc. raises $8 million and completes reverse merger.

Intuitive Venture PartnersJuly 7, 20212021, aeluma

Entera Bio Announces Positive Topline EB613 Phase 2 Biomarker Data

Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) announces positive topline EB613 phase 2 biomarker data

Intuitive Venture PartnersApril 6, 2021entera bio, 2021

SmartKem, Inc. Raises $24.6 Million and Completes Reverse Acquisition

SmartKem, Inc. Raises $24.6 million and completes reverse acquisition

Intuitive Venture PartnersFebruary 28, 20212021, smartkem

Angion Announces Closing 117 Million Initial Public Offering and Concurrent Private Placement

Angion Biomedica Corp. (NASDAQ: ANGN) announces closing of 117 million initial public offering and concurrent private placement

Intuitive Venture PartnersFebruary 9, 2021angion, 2021

9 Meters Biopharma Announces Agreement with the European Biomedical Research Institute of Salerno (EBRIS) to Continue Evaluation of Larazotide for COVID-19 Respiratory Complications

9 Meters Biopharma, Inc. (NASDAQ: NMTR) announces agreement with the European Biomedical Research Institute of Salerno (EBRIS) to continue evaluation of larazotide for COVID-19 respiratory complications

Intuitive Venture PartnersDecember 21, 20209 Meters, 2020

9 Meters Biopharma, Inc. Announces Closing of Offering of Common Stock

9 Meters Biopharma, Inc. (NASDAQ: NMTR) announces closing of offering of common stock

Intuitive Venture PartnersDecember 15, 20209 Meters, 2020

9 Meters Biopharma, Inc. Announces Proposed Public Offering of Common Stock

9 Meters Biopharma, Inc. (NASDAQ: NMTR) announces proposed public offering of common stock

Intuitive Venture PartnersDecember 10, 20209 Meters, 2020

Entera Bio Announces FDA Approval of IND Application for EB613 – an Oral Human Parathyroid Hormone (1-34) for the Treatment of Osteoporosis

Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) announces FDA approval of IND application for EB613 – an oral human parathyroid hormone (1-34) for the treatment of osteoporosis

Intuitive Venture PartnersDecember 10, 2020entera bio, 2020

Entera Bio Ltd Announces Completion of Enrollment In Phase 2 Clinical Trial of Eb613 In Osteoporosis

Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) announces completion of enrollment in phase 2 clinical trial of Eb613 In osteoporosis

Intuitive Venture PartnersNovember 9, 2020entera bio, 2020

Peernova Raises $31 Million in New Funding for Global Expansion

Peernova, an enterprise blockchain software startup that helps banks and financial institutions simplify reconciliation and other data processes, has raised $31 million in new funding.

Intuitive Venture PartnersOctober 24, 20192019, peernova

Angion Announces Strategic Additions to Management Team

Angion Biomedica Corp. (NASDAQ: ANGN) announces several strategic additions to its management team to support the future development and commercialization of ANG-3777

Intuitive Venture PartnersOctober 15, 20192019, angion

Angion Presents Late-Breaking Data on ANG-3777

Angion Biomedica Corp. (NASDAQ: ANGN) presents late-breaking data on ANG-377 in delayed graft function at the American Society of Nephrology Kidney Week 2019.

Intuitive Venture PartnersOctober 11, 20192019, angion

Innovate Biopharmaceuticals to Merge with RDD Pharma Creating New Gastroenterology Company

Innovate Biopharmaceuticals, Inc. (NASDAQ: INNT) to merge with RDD Pharma creating new gastroenterology company focused on specialty, rare and orphan diseases.

Intuitive Venture PartnersOctober 7, 2019innovate biopharmaceuticals, 2019

Entera Bio Reports Positive Results From a Phase 2 PK/PD Study

Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) reports positive results from a phase 2 PK/PD study of Oral PTH (1-34) in patients with hypoparathyroidism.

Intuitive Venture PartnersSeptember 23, 2019entera bio, 2019